Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2018-08-30 Governance Information
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Appendix 4G and Corporate Governance Statement 23 pages 434.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references compliance with ASX Listing Rules 4.7.3 and 4.10.3, which require lodging a corporate governance statement alongside the annual report. The content includes a key to disclosures related to the ASX Corporate Governance Council Principles and Recommendations, indicating it is a corporate governance statement or related disclosure. It is not the full annual report but a governance disclosure document submitted concurrently with the annual report. The document is not a report publication announcement since it contains substantive governance disclosure content rather than just announcing a report's availability. It is not an officer certification or a financial report. The document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-08-30 English
PTX-200 AML Study Expanded 3 pages 244.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX release providing an update on a clinical trial study (PTX-200 AML Study Expanded) by Prescient Therapeutics Ltd. It discusses enrollment completion, patient responses, and plans to expand the study. The content is focused on clinical trial progress and company operational updates rather than financial results, regulatory filings, or management changes. It does not contain financial statements, earnings data, or detailed management discussion. It is a corporate announcement related to clinical trial progress and operational updates, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like earnings release, annual report, or management information.
2018-08-29 English
Change in substantial holding 2 pages 133.3KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and references the Corporations Act 2001, Section 671B, which pertains to notices of change of interests of substantial holders. The content details changes in voting power, relevant interests, and shareholdings of a substantial holder in the company PRESCIENT THERAPEUTICS LIMITED. It includes tables of previous and current voting power, changes in relevant interests, and signatures. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document is not a financial report, management information, or any other category but specifically a substantial holder notice.
2018-08-14 English
June 2018 Appendix 4C - Quarterly 8 pages 450.4KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX release titled 'June 2018 Appendix 4C' for the quarter ended 30 June 2018. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as narrative on key activities during the quarter. Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rules (specifically Listing Rule 4.7B). The document is about 15,000 characters long and contains substantive financial data for the quarter, not just an announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2018
2018-07-30 English
US Patent Granted for PTX-200 for Ovarian Cancer Treatment 3 pages 386.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing the granting of a US patent for a drug candidate PTX-200 for the treatment of ovarian cancer. It provides background on the drug, ongoing clinical trials, and company information. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a corporate announcement about intellectual property and clinical progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about a patent grant, which is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2018-07-25 English
Change of Director's Interest Notices x2 5 pages 72.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is described as a 'Change of Director's Interest Notice' under ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the nature of interests, number of securities held before and after changes, and the nature of the changes (e.g., lapse of options). The document is a formal notification of insider share transactions by directors, not a financial report, earnings release, or management discussion. It fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains detailed transaction data, confirming it is the report itself, not just an announcement. Therefore, the correct classification is DIRS.
2018-07-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.